Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

WCD: Tacrolimus Ointment Is an Effective Treatment for Psoriasis of the Face and Intertriginous Areas By Jill Stein Special to DG News PARIS, FRANCE -- July 5, 2002 -- Tacrolimus 0.1 percent ointment is a safe and effective nonsteroidal alternative for patients with psoriasis on the face and/or intertriginous areas, according to researchers from the United States. Dr. Amy Krupnick, with the Mount Sinai School of Medicine in New York, New York, presented the results here at the 20th World Congress of Dermatology (WCD). Tacrolimus ointment (Protopic) is a new topical immunomodulator that has recently been approved in the United States for the treatment of atopic dermatitis. Dr. Krupnick and colleagues conducted an open-label, single-arm trial of tacrolimus 0.1 percent ointment in 21 patients who had psoriasis on the face and/or intertriginous areas. All patients had moderate to severe disease for a minimum of six months. Patients applied the ointment twice daily to the lesions for eight weeks. Clinical evaluations were done at baseline and at days 8, 15, 29, 43, and 57. The effectiveness of tacrolimus 0.1 percent ointment was demonstrated by the physicians’ assessment of individual signs and symptoms and global evaluation of change in psoriasis status compared to baseline. There was significant statistical improvement in erythema, infiltration, and desquamation from baseline to the end of treatment. In addition, complete clearance of psoriasis was seen as early as the first follow-up visit, which occurred on day 8. Approximately half of the patients had complete clearance at day 29. By day 43, almost 62 percent of patients had complete clearance, and by the end of treatment, 81 percent had clearance. Two patients experienced adverse events. One developed increased pruritus after the first two applications and the other experienced a sensation of warmth at the application site during the first few days of treatment. The adverse events were mild, self-limiting, and consistent with those reported in other studies, Dr. Krupnick said. Notably, no patient developed atrophy, striae, or telangiectasia during the trial. E-mail this page to a friend or colleague! To print, use this version